Analysis for the time trends of hepatoma mortality in China from 2004 to 2020

DING Shushu; GUO Haoyang; CHEN Hao; SUN Shu; SHI Wei; YUAN Hui

doi:10.16462/j.cnki.zhjbkz.2023.08.015

Volume 27 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(8): 963-967

DING Shushu, GUO Haoyang, CHEN Hao, SUN Shu, SHI Wei, YUAN Hui. Analysis for the time trends of hepatoma mortality in China from 2004 to 2020[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(8): 963-967. doi: 10.16462/j.cnki.zhjbkz.2023.08.015

Citation:

DING Shushu, GUO Haoyang, CHEN Hao, SUN Shu, SHI Wei, YUAN Hui. Analysis for the time trends of hepatoma mortality in China from 2004 to 2020[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(8): 963-967. doi: 10.16462/j.cnki.zhjbkz.2023.08.015

Citation:

PDF( 1943 KB)

Analysis for the time trends of hepatoma mortality in China from 2004 to 2020

doi: 10.16462/j.cnki.zhjbkz.2023.08.015

1.
Faculty of Prevention Medical Research, School of Public Health, Wannan Medical College, Wuhu 241002, China
2.
Preventive medicine, School of Public Health, Wannan Medical College, Wuhu 241002 China

Funds:

Cultivation Fund for Key Scientific Research Projects of Wanna Medical College WK2016Z07

Innovation and Entrepreneurship Training Program for College Students of China 201710368057

Innovation and Entrepreneurship Training Program for College Students of Anhui Province S202010368003

More Information

Corresponding author: YUAN Hui, E-mail: yuanhui0553@126.com
Received Date: 2022-03-23
Rev Recd Date: 2022-07-07

Available Online: 2023-09-02

Publish Date: 2023-08-10

Abstract

Abstract

Objective To analyze the standardized mortality rate of hepatoma and its trend variation among the Chinese population from 2004 to 2020, in order to provide a basis for formulating prevention and treatment strategies of hepatoma. Methods Mortality data were obtained from the the statistical information center of the National Health Commission. We extracted the mortality data of hepatoma from 2004 to 2020 and calculated the standardized mortality. The trend variation of standardized mortality of hepatoma in different regions and different age groups was compared by joinpoint model regression analysis. Results The standardized mortality rate of hepatoma among Chinese residents from 2004 to 2020 revealed that the rate was higher among rural residents compared to urban residents, and higher in males compared to females. The results of joinpoint regression showed that the standardized mortality of hepatoma in urban residents [average annual percent change(AAPC)=-2.38%, P < 0.001] was lower than that in rural residents (AAPC=-2.41%, P < 0.001); The annual decline rate of males was lower than that of females. The standardized mortality rate of hepatoma among urban residents aged 20- < 50, 55- < 60 and 70- < 85 showed a year-on-year decrease. In contrast, the standardized mortality rate of liver cancer among rural residents aged 25- < 50, 60- < 65 and 70- < 80 decreased year-on-year. Conclusions The overall mortality rate of liver cancer in China showed a downward trend from 2004 to 2020. However, disparities persist across gender, age, and region.
- Hepatoma,
- Mortality,
- Joinpoint,
- Time trend

FullText(HTML)

References(15)

References

[1]	International Agency for Research on Cancer. Cancer today 2020[EB/OL]. (2020-12-01)[2022-02-20]. http://gco.iarc.fr/tosay/home.
[2]	中国疾病预防控制中心慢性非传染性疾病预防控制中心, 国家卫生健康委统计信息中心. 中国死因监测数据集2020[M]. 北京: 中国科学技术出版社, 2021: 59-60. National Center for Chronic and Non-communicable Disease Prevention and Control, Chinese Center for Disease Control and Prevention, Statistical Information Center of the National Health and Family Planning Commission. China death cause monitoring data set 2020[M]. Beijing: Science Popularization press, 2021: 59-60.
[3]	高静, 吴春晓, 谢丽, 等. 上海市2006―2008年原发性肝癌发病及死亡资料分析[J]. 肿瘤, 2012, 32(7): 526-530. DOI: 10.3781/j.issn.1000-7431.2012.07.008. Gao J, Wu CX, Xie L, et al. Incidence and mortality of primary liver cancer in Shanghai, 2006-2008[J]. Tumor, 2012, 32 (7): 526-530. DOI: 10.3781/j.issn.1000-7431.2012.07.008.
[4]	国家卫生健康委员会. 2021中国卫生健康统计年鉴[M]. 北京: 中国协和医科大学出版社, 2021: 257-309. National Health Commission. China Health Statistics Yearbook 2021[M]. Beijing: China Union Medical College Press, 2021: 257-309.
[5]	Goovaerts P, Xiao H. Geographical, temporal and racial disparities in late-stage prostate cancer incidence across Florida: a multiscale joinpoint regression analysis[J]. Int J Health Geogr, 2011, 10: 63. DOI: 10.1186/1476-072X-10-63.
[6]	Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China[J]. Liver Cancer, 2013, 2(1): 31-39. DOI: 10.1159/000346220.
[7]	Cao M, Li H, Sun D, et al. Cancer screening in China: the current status, challenges and suggestions[J]. Cancer Lett, 2021, 506: 120-127. DOI: 10.1016/j.canlet.2021.02.017.
[8]	余钦, 张永辉, 朱健, 等. 启东地区中老年HBV慢性感染人群合并脂肪肝的关联因素分析[J]. 中华疾病控制杂志, 2020, 24(9): 1032-1036, 1078. DOI: 10.16462/j.cnki.zhjbkz.2020.09.008. Yu Q, Zhang YH, Zhu J, et al. An analysis of fatty liver and related factors of middle-aged and elderly people from a HBV infection cohort in Qidong area[J]. Chin J Dis Control Prev. 2020, 24(9): 1032-1036, 1078. DOI: 10.16462/j.cnki.zhjbkz.2020.09.008.
[9]	张思维, 郑荣寿, 曾红梅, 等. 1989-2008年中国肝癌发病性别、地区及年龄变化分析[J]. 中华预防医学杂志, 2014, 48(5): 355-360. DOI: 10.3760/cma.j.issn.0253-9624.2014.05.005. Zhang SW, Zheng RS, Zeng HM, et al. The incidence differences among sex, geographical areas and mean age of diagnosis for liver cancer in China, 1989-2008[J]. Chin J Prev Med, 2014, 48(5): 355-360. DOI: 10.3760/cma.j.issn.0253-9624.2014.05.005.
[10]	梁智恒, 彭侠彪, 岑惠珊, 等. 广东省中山市1970~2010年肝癌发病概况[J]. 中国肿瘤, 2015, 24(8): 631-637. DOI: 10.11735/j.issn.1004-0242.2015.08.A002. Liang ZH, Peng XB, Cen HS, et al. An analysis of incidence of liver cancer in Zhongshan, 1970~2010[J]. China Cancer, 2015, 24(8): 631-637. DOI: 10.11735/j.issn.1004-0242.2015.08.A002.
[11]	陈仁友, 李云峰, 隆伟, 等. 山东省2016-2017年人群烟草使用及其影响因素调查[J]. 中华流行病学杂志, 2021, 42(7): 1200-1204. DOI: 10.3760/cma.j.cn112338-20200903-01123. Chen RY, Li YF, Long W, et al. Survey on tobacco use and associated factors in population in Shandong Province, 2016-2017[J]. Chin J Epidemiol, 2021, 42(7): 1200-1204. DOI: 10.3760/cma.j.cn112338-20200903-01123.
[12]	朴玮, 赵丽云, 房红芸, 等. 中国18岁及以上成人饮酒行为现况[J]. 中国食物与营养, 2021, 27(10): 15-19. DOI: 10.19870/j.cnki.11-3716/ts.2021.10.009. Pu W, Zhao LY, Fang HY, et al. Current status of drinking behavior among adults aged 18 and over in China[J]. Food Nutr China, 2021, 27(10): 15-19. DOI: 10.19870/j.cnki.11-3716/ts.2021.10.009.
[13]	杨黎明, 李小攀, 杨琛, 等. 2002-2011年上海市浦东新区居民原发性肝癌发病及生存情况分析[J]. 中华流行病学杂志, 2012, 33(10): 1016-1020. DOI: 10.3760/cma.j.issn0254-6450.2012.10.005. Yang LM, Li XP, Yang C, et al. Incidence and survival condition of primary liver cancer among residents in Pudong district of Shanghai, from 2002 to 2011[J]. Chin J Epidemiol, 2012, 33(10): 1016-1020. DOI: 10.3760/cma.j.issn0254-6450.2012.10.005.
[14]	Yeh YP, Hu TH, Cho PY, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan[J]. Hepatology, 2014, 59(5): 1840-1849. DOI: 10.1002/hep.26703.
[15]	中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 中华肝脏病杂志. 2021, 29(3): 216-226. DOI: 10.3760/cma.j.cn501113-20210210-00082. Chinese Society of Hepatology, Chinese Medical Association. The consensus of secondary prevention for primary liver cancer (2021 version)[J]. J Prac Hepatol. 2021, 29(3): 216-226. DOI: 10.3760/cma.j.cn501113-20210210-00082.